Wall Street analysts shuffled their outlooks on several notable stocks this Friday, with moves ranging from aggressive bullishness to dramatic target cuts. Here's what the pros are forecasting.

Capital One Gets a Boost

BTIG raised its price target on Capital One Financial Corporation (COF) from $264 to $308, while analyst Vincent Caintic maintained a Buy rating. The new target implies roughly 24% upside from Wednesday's closing price of $248.27. That's the kind of potential gain that gets investors' attention, suggesting BTIG sees meaningful catalysts ahead for the financial services giant.

Agios Pharmaceuticals Draws Double Upgrades

Agios Pharmaceuticals, Inc. (AGIO) caught positive attention from two firms. HC Wainwright & Co. raised its price target substantially from $48 to $62, with analyst Emily Bodnar maintaining a Buy rating. Separately, Leerink Partners increased its target from $34 to $40, as analyst Andrew Berens kept an Outperform rating on the stock. Agios shares closed at $29.17 on Wednesday, meaning HC Wainwright's target suggests more than doubling from current levels.

Lexaria Bioscience Faces Reality Check

Not all news was rosy. HC Wainwright & Co. slashed its price target on Lexaria Bioscience Corp (LEXX) from $4 to $1.50, though analyst Yi Chen maintained a Buy rating. With shares closing at $0.56 on Wednesday, even the reduced target implies significant upside. But the dramatic 62.5% cut to the target suggests the firm is recalibrating expectations substantially lower, even while staying constructive on the stock's direction.

These analyst moves reflect the ongoing reassessment of valuations and growth prospects across different sectors, from financial services to biotechnology. Whether these targets prove accurate remains to be seen, but they offer a window into how Wall Street's research desks are thinking about these companies right now.